Overall , 367 ( 92.2 % ) of 398 patients completed the study ( BRV : 93.9 % , 88.9 % , and 94.0 % for 20 , 50 , and 100 mg/day , respectively ; PBO : 92.0 % ) and 345 ( 86.7 % ) of 398 patients continued into long-term follow-up studies ( BRV : 87.9 % , 82.8 % , and 88.0 % for 20 , 50 , and 100 mg/day , respectively ; PBO : 88.0 % ) .